Trials / Completed
CompletedNCT01659567
A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C
Prospective, Observational Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Patients With Hepatitis C in Georgia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 516 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective observational study will investigate predictive values of virological response in pegylated interferon alfa-2a (Pegasys)/ribavirin (Copegus) treatment-naive participants with chronic hepatitis C. Participants will be treated with pegylated interferon alfa-2a and ribavirin as prescribed by the physician. Data will be collected for a maximum of 96 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegylated Interferon Alfa-2a | Pegylated interferon alfa-2a will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling. |
| DRUG | Ribavirin | Ribavirin will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling. |
Timeline
- Start date
- 2011-04-06
- Primary completion
- 2015-10-20
- Completion
- 2015-10-20
- First posted
- 2012-08-08
- Last updated
- 2017-10-03
- Results posted
- 2017-10-03
Locations
3 sites across 1 country: Georgia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01659567. Inclusion in this directory is not an endorsement.